Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine

European Journal of Pharmaceutical Sciences

Volumn 12, Issue 1, 2000, Pages 3-12

  Suzuki, Hiroshi ^a   Sugiyama, Yuichi ^a  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Efflux transporters; Organic anions; Small intestine

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ATORVASTATIN; BUSPIRONE; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; ERYTHROMYCIN; FELODIPINE; FUROSEMIDE; GLYCOPROTEIN P; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; PRAVASTATIN; PROBENECID; PRODRUG; PROTEINASE INHIBITOR; RIFAMPICIN; SALICYLAMIDE; SAQUINAVIR; TACROLIMUS; TERFENADINE; UNINDEXED DRUG;

CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; ENZYME SPECIFICITY; FOOD DRUG INTERACTION; FRUIT JUICE; HUMAN; INTESTINE CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINE, SMALL; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PRODRUGS; XENOBIOTICS;

EID: 0033739725     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00178-0     Document Type: Review

References (95)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Drug interactions with grapefruit juice
3. Intestinal MDR transport proteins and P450 enzyme as barriers to oral drug delivery
4. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells
5. Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations
6. Metabolism of L-alpha-methyldopa in cultured human intestinal epithelial (Caco-2) cell monolayers: comparison with metabolism in vivo
7. Polarized efflux of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelial cell monolayers
8. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism
9. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
10. Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates
11. Systemic intestinal metabolism of 1-naphthol: a study in the isolated vascularly perfused rat small intestine
12. Absorption and presystemic glucuronidation of 1-naphthol in the vascularly fluorocarbon emulsion perfused rat small intestine: the influence of 1-naphthol concentration, perfusate flow and noradrenaline
13. Hepatic, intestinal and renal transport of 1-naphthol-β-D-glucuronide in mutant rats with hereditary-conjugated hyperbilirubinemia
14. Cytochrome P450 3A: ontogeny and drug disposition
15. Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation
16. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice
17. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein
18. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum
19. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
20. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation
21. Drug interactions with grapefruit juice
22. Calcein is excreted from the intestinal mucosal cell membrane by the active transport system
23. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy
24. Inhibition of cytochrome P450 3A (CYP3A) in human intestinal and liver microsomes: comparison of K(i) values and impact of CYP3A5 expression
25. The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
26. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats
27. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
28. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
29. Influence of grapefruit juice on cisapride pharmacokinetics
30. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species
31. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake
32. Molecular and physical mechanisms of first-pass extraction
33. Effect of rifampin on tacrolimus pharmacokinetics in healthy volunteers
34. Estimations of intestinal and liver first-pass metabolism in vivo: studies on gentisamide conjugation in the rat
35. Characterization of the transport properties of cloned rat multidrug resistance associated protein 3 (MRP3)
36. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2)
37. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (MRP3)
38. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
39. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
40. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver
41. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach
42. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
43. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
44. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
45. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance
46. Glucuronidation in isolated perfused rat intestinal segments after mucosal and serosal administration of 1-naphthol
47. Interaction between grapefruit juice and midazolam in humans
48. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
49. 35S]sulphate into 1-naphthol by the isolated mucosa of guinea pig jejunum and colon
50. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene
51. Peptide transporters in the intestine and the kidney
52. Grapefruit juice substantially increases plasma concentrations of buspirone
53. Grapefruit juice-simvastatin interactions: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
54. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
55. Is the role of the small intestine in first-pass metabolism overemphasized?
56. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
57. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
58. Sequence of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical
59. Effect of grapefruit juice ingestion - pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men
60. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells
61. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein
62. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
63. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes
64. Effect of oral pretreatment with indomethacin on the intestinal first-pass metabolism of salicylamide in rabbits
65. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a GP Iib/IIIa receptor antagonist, in rat small intestine
66. A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug
67. Glutathione-conjugate transport by human colon adenocarcinoma cells (Caco-2 cells)
68. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
69. First-pass metabolism of midazolam by the human intestine
70. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam
71. Absorption and metabolism of acetaminophen by the in situ perfused rat small intestine preparation
72. Pharmacokinetics of felodipine in patients with liver disease
73. Restricted intestinal absorption of some b-lactam antibiotics by an energy-dependent efflux system in rat intestine
74. The secretory intestinal transport of some β-lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption
75. Effects of ketoconazole on digoxin absorption and disposition in rat
76. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
77. Multiple systems for the biliary excretion of organic anions in rats: liquiritigenin conjugates as model compounds
78. Biliary excretion of glycyrrhizin in rats: kinetic basis for the multiplicity in the bile canalicular transport of organic anions
79. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
80. Drug metabolism and metabolite transport in the small and large intestine: experiments with 1-naphthol and phenolphthalein by luminal and contraluminal administration in the isolated guinea pig mucosa
81. 1-Naphthol metabolism and metabolite transport in the small and large intestine. II: effect of sulphate and phosphate ion omission, and of 2,6-dichloro-4-nitrophenol in the isolated guinea pig mucosa
82. 2-Naphthol metabolism and metabolite transport in the isolated guinea pig mucosa: further evidence for compartmentation of intestinal drug metabolism
83. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2
84. Selective inhibitors of MDR1 and CYP3A4
85. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells
86. The biliary excretion systems for conjugative metabolites: comparison of glucuronide and sulfate in Eisai hyperbilirubinemic rats (EHBR)
87. Kinetic analysis of hepatobiliary transport for conjugative metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugative hyperbilirubinemia
88. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
89. In vitro and in vivo drug interactions involving human CYP3A
90. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
91. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2
92. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
93. Vectorial release of sulfoconjugates in the vascularly perfused mouse small intestine
94. First-pass metabolism of salicylamide. Studies in the once-through vascularly perfused rat intestine-liver preparation
95. Characterization of human small intestinal cytochromes P450